Vertex Pharmaceuticals Incorporated Company Profile (NASDAQ:VRTX)

About Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated logoVertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VRTX
  • CUSIP: 92532F10
Key Metrics:
  • Previous Close: $117.66
  • 50 Day Moving Average: $102.02
  • 200 Day Moving Average: $87.66
  • 52-Week Range: $71.46 - $118.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 37.95
  • P/E Growth: 0.99
  • Market Cap: $29.23B
  • Outstanding Shares: 248,438,000
  • Beta: 0.79
Profitability:
  • Net Margins: -6.76%
  • Return on Equity: -2.15%
  • Return on Assets: -0.98%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 2.08%
  • Quick Ratio: 1.98%

Analyst Ratings

Consensus Ratings for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (?)
Ratings Breakdown: 10 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $108.10 (8.12% downside)

Analysts' Ratings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/23/2017Barclays PLCReiterated RatingEqual Weight$90.00 -> $100.00LowView Rating Details
4/4/2017Credit Suisse Group AGReiterated RatingHold$108.00MediumView Rating Details
4/2/2017HC WainwrightReiterated RatingNeutral$85.00LowView Rating Details
3/31/2017JMP SecuritiesReiterated RatingOutperform$115.00 -> $121.00MediumView Rating Details
3/31/2017Maxim GroupUpgradeHold -> Buy$143.00LowView Rating Details
3/30/2017Cowen and CompanyReiterated RatingMarket Perform$75.00LowView Rating Details
3/29/2017Citigroup IncBoost Price TargetBuy$105.00 -> $124.00LowView Rating Details
3/29/2017Robert W. BairdReiterated RatingOutperform$115.00LowView Rating Details
3/29/2017Stifel NicolausBoost Price TargetBuy$100.00 -> $129.00HighView Rating Details
3/29/2017BMO Capital MarketsUpgradeMarket Perform -> Outperform$89.67 -> $100.00HighView Rating Details
3/29/2017Jefferies Group LLCReiterated RatingBuy$100.00HighView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformMediumView Rating Details
3/14/2017ArgusReiterated RatingBuy$115.00 -> $92.95LowView Rating Details
2/27/2017Oppenheimer Holdings Inc.Reiterated RatingHoldN/AView Rating Details
1/20/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
1/3/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
12/25/2016Piper Jaffray CompaniesSet Price TargetBuy$129.00N/AView Rating Details
12/7/2016Janney Montgomery ScottReiterated RatingNeutral$98.00N/AView Rating Details
11/1/2016William BlairDowngradeOutperform -> Market Perform$105.00 -> $81.00N/AView Rating Details
10/12/2016Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
9/13/2016Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
7/28/2016Morgan StanleyLower Price TargetOverweight$140.00 -> $139.00N/AView Rating Details
4/28/2016Goldman Sachs Group IncDowngradeBuy -> Neutral$109.00 -> $88.00N/AView Rating Details
3/28/2016GuggenheimLower Price TargetBuy$145.00 -> $114.00N/AView Rating Details
3/15/2016Bank of America CorpReiterated RatingNeutral$108.00N/AView Rating Details
9/15/2015NomuraInitiated CoverageBuy$162.00N/AView Rating Details
7/31/2015Deutsche Bank AGReiterated RatingBuy$155.00N/AView Rating Details
7/7/2015BTIG ResearchLower Price TargetBuy$200.00 -> $180.00N/AView Rating Details
6/5/2015Canaccord GenuityReiterated RatingBuy$150.00N/AView Rating Details
(Data available from 4/24/2015 forward)

Earnings

Earnings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Earnings by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Earnings History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2017        
1/25/2017Q4 2016$0.29$0.35$453.40 million$458.71 millionViewN/AView Earnings Details
10/25/2016Q316$0.18$0.16$423.53 million$413.78 millionViewListenView Earnings Details
7/27/2016Q216$0.21$0.24$428.08 million$431.61 millionViewListenView Earnings Details
4/27/2016Q116$0.29$0.09$439.94 million$398.10 millionViewListenView Earnings Details
1/27/2016Q4$0.17$0.17$406.30 million$417.94 millionViewListenView Earnings Details
10/28/2015Q315($0.60)($0.13)$245.84 million$309.82 millionViewListenView Earnings Details
7/29/2015Q215($0.58)($0.54)$149.49 million$166.00 millionViewListenView Earnings Details
4/29/2015Q115($0.75)($0.62)$142.38 million$138.51 millionViewListenView Earnings Details
1/28/2015Q414($0.65)($0.55)$137.50 million$144.56 millionViewListenView Earnings Details
10/28/2014Q314($0.62)($0.37)$146.20 million$179.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.71)($0.61)$131.85 million$138.42 millionViewListenView Earnings Details
5/1/2014Q114($0.68)($0.65)$134.46 million$118.50 millionViewN/AView Earnings Details
1/29/2014Q413($0.49)($0.56)$221.08 million$351.20 millionViewListenView Earnings Details
10/29/2013Q413($0.33)($0.32)$278.80 million$222.00 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.18)($0.26)$308.02 million$310.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)$0.03$307.85 million$328.40 millionViewN/AView Earnings Details
1/29/2013Q4 2012($0.07)($0.35)$318.53 million$334.00 millionViewN/AView Earnings Details
11/1/2012Q312$0.34$0.13$377.14 million$336.00 millionViewN/AView Earnings Details
7/30/2012$0.68$0.46ViewN/AView Earnings Details
4/26/2012$0.57$0.43ViewN/AView Earnings Details
2/2/2012$0.76$0.74ViewN/AView Earnings Details
10/27/2011$0.17$0.70ViewN/AView Earnings Details
7/28/2011($1.00)($0.67)ViewN/AView Earnings Details
5/3/2011($1.09)($0.91)ViewN/AView Earnings Details
2/3/2011($0.93)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
2017 EPS Consensus Estimate: $0.54
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.02)$0.04$0.02
Q2 20173$0.02$0.47$0.19
Q3 20173$0.09$0.15$0.12
Q4 20173$0.12$0.33$0.22
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/29/2013quarterly$0.402/20/20133/13/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 94.85%
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Institutional Ownership by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/5/2017Jeffrey ChodakewitzCMOSell8,021$114.00$914,394.00View SEC Filing  
4/3/2017Jeffrey ChodakewitzCMOSell2,291$108.85$249,375.35View SEC Filing  
3/29/2017Amit SachdevEVPSell80,500$107.63$8,664,215.00View SEC Filing  
3/29/2017Jeffrey ChodakewitzCMOSell13,750$106.65$1,466,437.50View SEC Filing  
3/29/2017Paul M SilvaSVPSell1,688$106.30$179,434.40View SEC Filing  
1/11/2017Joshua S BogerDirectorSell8,000$82.48$659,840.00View SEC Filing  
1/4/2017Joshua S BogerDirectorSell6,500$77.13$501,345.00View SEC Filing  
12/29/2016Joshua S BogerDirectorSell6,500$74.33$483,145.00View SEC Filing  
12/21/2016Joshua S BogerDirectorSell6,500$74.16$482,040.00View SEC Filing  
12/14/2016Joshua S BogerDirectorSell6,500$77.52$503,880.00View SEC Filing  
11/30/2016Joshua S BogerDirectorSell6,500$83.48$542,620.00View SEC Filing  
11/23/2016Joshua S BogerDirectorSell6,500$86.47$562,055.00View SEC Filing  
11/16/2016Joshua S BogerDirectorSell6,500$91.55$595,075.00View SEC Filing  
11/10/2016Paul M SilvaSVPSell5,062$90.98$460,540.76View SEC Filing  
11/9/2016Joshua S BogerDirectorSell6,500$90.98$591,370.00View SEC Filing  
11/9/2016Stuart A ArbuckleEVPSell1,208$90.00$108,720.00View SEC Filing  
11/2/2016Joshua S BogerDirectorSell6,500$77.75$505,375.00View SEC Filing  
10/26/2016Joshua S BogerDirectorSell6,500$79.26$515,190.00View SEC Filing  
10/19/2016Joshua S BogerDirectorSell6,500$81.84$531,960.00View SEC Filing  
10/12/2016Joshua S BogerDirectorSell6,500$81.14$527,410.00View SEC Filing  
10/5/2016Joshua S BogerDirectorSell6,500$87.44$568,360.00View SEC Filing  
10/3/2016Stuart A ArbuckleEVPSell1,208$86.46$104,443.68View SEC Filing  
9/28/2016Joshua S BogerDirectorSell6,500$88.15$572,975.00View SEC Filing  
9/21/2016Joshua S BogerDirectorSell6,500$90.82$590,330.00View SEC Filing  
9/14/2016Joshua S BogerDirectorSell6,500$92.37$600,405.00View SEC Filing  
9/7/2016Joshua S BogerDirectorSell6,500$95.66$621,790.00View SEC Filing  
8/31/2016Joshua S BogerDirectorSell6,500$94.62$615,030.00View SEC Filing  
8/24/2016Joshua S BogerDirectorSell7,500$100.46$753,450.00View SEC Filing  
8/22/2016Joshua S BogerDirectorSell1,100$100.79$110,869.00View SEC Filing  
8/17/2016Joshua S BogerDirectorSell6,900$99.63$687,447.00View SEC Filing  
8/11/2016Joshua S BogerDirectorSell900$100.19$90,171.00View SEC Filing  
8/10/2016Joshua S BogerDirectorSell7,100$100.24$711,704.00View SEC Filing  
8/3/2016Joshua S BogerDirectorSell47,000$100.66$4,731,020.00View SEC Filing  
7/27/2016Joshua S BogerDirectorSell6,500$95.93$623,545.00View SEC Filing  
7/20/2016Joshua S BogerDirectorSell6,500$90.33$587,145.00View SEC Filing  
7/13/2016Joshua S BogerDirectorSell6,500$88.81$577,265.00View SEC Filing  
7/6/2016Joshua S BogerDirectorSell5,140$88.99$457,408.60View SEC Filing  
6/29/2016Joshua S BogerDirectorSell5,130$84.82$435,126.60View SEC Filing  
6/22/2016Joshua S BogerDirectorSell5,130$86.61$444,309.30View SEC Filing  
6/15/2016Joshua S BogerDirectorSell5,130$91.18$467,753.40View SEC Filing  
6/8/2016Joshua S BogerDirectorSell5,130$94.95$487,093.50View SEC Filing  
6/1/2016Joshua S BogerDirectorSell5,130$93.65$480,424.50View SEC Filing  
5/25/2016Joshua S BogerDirectorSell5,130$89.09$457,031.70View SEC Filing  
5/18/2016Joshua S BogerDirectorSell5,130$81.18$416,453.40View SEC Filing  
5/16/2016Amit SachdevEVPSell117$81.67$9,555.39View SEC Filing  
5/16/2016Ian F SmithCFOSell202$82.06$16,576.12View SEC Filing  
5/11/2016Joshua S BogerDirectorSell5,130$86.50$443,745.00View SEC Filing  
5/9/2016Paul M SilvaSVPSell3,000$87.63$262,890.00View SEC Filing  
5/4/2016Joshua S BogerDirectorSell5,130$81.02$415,632.60View SEC Filing  
4/27/2016Joshua S BogerDirectorSell5,130$83.67$429,227.10View SEC Filing  
4/20/2016Joshua S BogerDirectorSell5,130$84.10$431,433.00View SEC Filing  
4/13/2016Joshua S BogerDirectorSell5,130$84.27$432,305.10View SEC Filing  
4/6/2016Joshua S BogerDirectorSell5,130$89.56$459,442.80View SEC Filing  
3/30/2016Joshua S BogerDirectorSell5,130$78.83$404,397.90View SEC Filing  
3/23/2016Joshua S BogerDirectorSell5,130$81.38$417,479.40View SEC Filing  
3/16/2016Joshua S BogerDirectorSell5,130$79.65$408,604.50View SEC Filing  
3/2/2016Joshua S BogerDirectorSell5,130$91.80$470,934.00View SEC Filing  
2/24/2016Joshua S BogerDirectorSell5,130$85.25$437,332.50View SEC Filing  
2/17/2016Joshua S. BogerDirectorSell5,130$86.93$445,950.90View SEC Filing  
2/10/2016Joshua S. BogerDirectorSell5,130$82.57$423,584.10View SEC Filing  
2/3/2016Ian F. SmithCFOSell12,084$90.84$1,097,710.56View SEC Filing  
2/3/2016Jeffrey M. LeidenCEOSell9,834$90.82$893,123.88View SEC Filing  
2/3/2016Joshua S. BogerDirectorSell5,130$90.81$465,855.30View SEC Filing  
2/3/2016Paul M. SilvaSVPSell5,062$90.82$459,730.84View SEC Filing  
2/3/2016Stuart A. ArbuckleEVPSell6,042$90.82$548,734.44View SEC Filing  
2/2/2016Jeffrey ChodakewitzCMOSell2,375$91.38$217,027.50View SEC Filing  
1/27/2016Joshua S. BogerDirectorSell11,200$93.22$1,044,064.00View SEC Filing  
1/20/2016Joshua S. BogerDirectorSell10,400$93.69$974,376.00View SEC Filing  
1/13/2016Joshua S. BogerDirectorSell10,400$98.41$1,023,464.00View SEC Filing  
1/6/2016Joshua S. BogerDirectorSell10,400$121.96$1,268,384.00View SEC Filing  
1/4/2016Yuchun LeeDirectorSell1,125$122.21$137,486.25View SEC Filing  
12/30/2015Joshua S. BogerDirectorSell10,400$127.15$1,322,360.00View SEC Filing  
12/21/2015Joshua S. BogerDirectorSell10,400$119.26$1,240,304.00View SEC Filing  
12/9/2015Joshua S. BogerDirectorSell10,400$120.80$1,256,320.00View SEC Filing  
12/4/2015Stuart A. ArbuckleEVPSell4,531$123.98$561,753.38View SEC Filing  
12/2/2015Joshua S. BogerDirectorSell10,400$130.91$1,361,464.00View SEC Filing  
12/1/2015David AltshulerEVPSell5,000$131.00$655,000.00View SEC Filing  
12/1/2015Yuchun LeeDirectorSell1,125$129.65$145,856.25View SEC Filing  
11/23/2015Joshua S. BogerDirectorSell10,400$132.18$1,374,672.00View SEC Filing  
11/11/2015Joshua S. BogerDirectorSell10,400$118.59$1,233,336.00View SEC Filing  
11/4/2015Joshua S. BogerDirectorSell10,400$124.23$1,291,992.00View SEC Filing  
11/2/2015Yuchun LeeDirectorSell1,125$126.19$141,963.75View SEC Filing  
10/28/2015Joshua S. BogerDirectorSell10,400$119.01$1,237,704.00View SEC Filing  
10/21/2015Joshua S. BogerDirectorSell10,400$108.82$1,131,728.00View SEC Filing  
10/14/2015Joshua S. BogerDirectorSell10,400$112.62$1,171,248.00View SEC Filing  
10/7/2015Joshua S. BogerDirectorSell10,400$109.61$1,139,944.00View SEC Filing  
10/2/2015Elaine UllianDirectorSell20,000$110.00$2,200,000.00View SEC Filing  
10/1/2015Stuart A. ArbuckleEVPSell12,417$104.71$1,300,184.07View SEC Filing  
10/1/2015Yuchun LeeDirectorSell1,125$104.64$117,720.00View SEC Filing  
9/30/2015Joshua S. BogerDirectorSell10,400$103.14$1,072,656.00View SEC Filing  
9/23/2015Joshua S. BogerDirectorSell10,400$111.89$1,163,656.00View SEC Filing  
9/16/2015Joshua S. BogerDirectorSell10,400$133.24$1,385,696.00View SEC Filing  
9/9/2015Joshua S. BogerDirectorSell10,400$131.41$1,366,664.00View SEC Filing  
9/4/2015Stuart A. ArbuckleEVPSell9,063$125.77$1,139,853.51View SEC Filing  
9/2/2015Joshua S. BogerDirectorSell10,400$125.85$1,308,840.00View SEC Filing  
9/1/2015Yuchun LeeDirectorSell1,125$125.40$141,075.00View SEC Filing  
8/26/2015Joshua S. BogerDirectorSell10,400$124.71$1,296,984.00View SEC Filing  
8/19/2015Joshua S. BogerDirectorSell10,400$139.93$1,455,272.00View SEC Filing  
8/12/2015Joshua S BogerDirectorSell10,400$135.83$1,412,632.00View SEC Filing  
7/22/2015Joshua S BogerDirectorSell10,400$130.92$1,361,568.00View SEC Filing  
7/15/2015Joshua S BogerDirectorSell12,200$133.98$1,634,556.00View SEC Filing  
7/13/2015Paul M SilvaSVPSell1,125$123.79$139,263.75View SEC Filing  
7/8/2015Joshua S BogerDirectorSell11,700$122.74$1,436,058.00View SEC Filing  
7/2/2015Jeffrey ChodakewitzCMOSell2,291$129.36$296,363.76View SEC Filing  
7/1/2015Joshua S BogerDirectorSell11,700$125.60$1,469,520.00View SEC Filing  
6/24/2015Joshua S BogerDirectorSell11,700$130.41$1,525,797.00View SEC Filing  
6/17/2015Joshua S BogerDirectorSell11,700$123.90$1,449,630.00View SEC Filing  
6/10/2015Joshua S BogerDirectorSell11,700$125.02$1,462,734.00View SEC Filing  
5/20/2015Joshua S BogerDirectorSell11,700$126.73$1,482,741.00View SEC Filing  
5/6/2015Joshua S BogerDirectorSell11,700$122.79$1,436,643.00View SEC Filing  
5/5/2015Paul M SilvaSVPSell4,101$123.68$507,211.68View SEC Filing  
4/29/2015Joshua S BogerDirectorSell11,700$124.59$1,457,703.00View SEC Filing  
4/27/2015Paul M SilvaSVPSell1,125$129.74$145,957.50View SEC Filing  
4/27/2015Stuart A ArbuckleEVPSell61,480$129.36$7,953,052.80View SEC Filing  
4/27/2015Terrence C KearneyDirectorSell68,125$129.11$8,795,618.75View SEC Filing  
4/22/2015Joshua S BogerDirectorSell11,700$132.46$1,549,782.00View SEC Filing  
4/15/2015Joshua S BogerDirectorSell11,700$129.25$1,512,225.00View SEC Filing  
4/13/2015Paul M SilvaSVPSell1,125$128.60$144,675.00View SEC Filing  
4/8/2015Joshua S BogerDirectorSell11,700$123.26$1,442,142.00View SEC Filing  
4/6/2015Margaret G McglynnDirectorSell12,500$118.36$1,479,500.00View SEC Filing  
4/2/2015Jeffrey ChodakewitzCMOSell2,291$115.50$264,610.50View SEC Filing  
4/1/2015Joshua S BogerDirectorSell11,700$115.87$1,355,679.00View SEC Filing  
3/25/2015Joshua S BogerDirectorSell11,700$120.76$1,412,892.00View SEC Filing  
3/23/2015Amit SachdevEVPSell17,083$132.28$2,259,739.24View SEC Filing  
3/23/2015Ian F SmithCFOSell6,042$125.67$759,298.14View SEC Filing  
3/23/2015Paul M SilvaSVPSell2,250$125.65$282,712.50View SEC Filing  
3/18/2015Amit SachdevEVPSell12,000$130.00$1,560,000.00View SEC Filing  
2/5/2015Paul M SilvaSVPSell1,688$109.75$185,258.00View SEC Filing  
2/4/2015Joshua S BogerDirectorSell5,700$108.81$620,217.00View SEC Filing  
2/3/2015Paul M SilvaSVPSell2,063$108.89$224,640.07View SEC Filing  
2/2/2015Jeffrey ChodakewitzCMOSell1,188$109.60$130,204.80View SEC Filing  
1/28/2015Joshua S BogerDirectorSell10,688$122.78$1,312,272.64View SEC Filing  
1/26/2015Paul M SilvaSVPSell1,125$125.62$141,322.50View SEC Filing  
1/21/2015Joshua S BogerDirectorSell10,500$125.08$1,313,340.00View SEC Filing  
1/14/2015Joshua S BogerDirectorSell10,500$120.16$1,261,680.00View SEC Filing  
1/9/2015Amit SachdevEVPSell12,000$125.00$1,500,000.00View SEC Filing  
1/9/2015Bruce I SachsDirectorSell9,861$125.04$1,233,019.44View SEC Filing  
1/7/2015Joshua S BogerDirectorSell10,500$119.32$1,252,860.00View SEC Filing  
1/2/2015Jeffrey ChodakewitzCMOSell2,291$122.54$280,739.14View SEC Filing  
12/22/2014Joshua S BogerDirectorSell10,500$117.65$1,235,325.00View SEC Filing  
12/17/2014Joshua S BogerDirectorSell10,500$110.66$1,161,930.00View SEC Filing  
12/15/2014Jeffrey M LeidenCEOSell50,017$114.97$5,750,454.49View SEC Filing  
12/12/2014Paul M SilvaSVPSell2,813$120.08$337,785.04View SEC Filing  
11/28/2014Amit SachdevEVPSell12,000$120.00$1,440,000.00View SEC Filing  
11/28/2014Bruce I SachsDirectorSell10,000$120.03$1,200,300.00View SEC Filing  
11/28/2014Paul M SilvaSVPSell8,164$119.85$978,455.40View SEC Filing  
11/26/2014Joshua S BogerDirectorSell10,500$114.54$1,202,670.00View SEC Filing  
11/6/2014Bruce I SachsDirectorSell9,900$115.21$1,140,579.00View SEC Filing  
11/5/2014Bruce I SachsDirectorSell30,100$112.62$3,389,862.00View SEC Filing  
11/3/2014Joshua S BogerDirectorSell127,411$112.20$14,295,514.20View SEC Filing  
10/29/2014Joshua S BogerDirectorSell10,500$109.44$1,149,120.00View SEC Filing  
10/28/2014Amit SachdevEVPSell12,000$115.00$1,380,000.00View SEC Filing  
10/28/2014David AltshulerDirectorSell2,000$114.75$229,500.00View SEC Filing  
10/28/2014Jeffrey ChodakewitzCMOSell3,438$115.00$395,370.00View SEC Filing  
10/27/2014Paul M SilvaSVPSell1,125$110.03$123,783.75View SEC Filing  
10/13/2014Paul M SilvaSVPSell1,125$107.89$121,376.25View SEC Filing  
10/7/2014Jeffrey ChodakewitzCMOSell3,436$104.26$358,237.36View SEC Filing  
10/6/2014David AltshulerDirectorSell1,405$109.75$154,198.75View SEC Filing  
10/1/2014Elaine UllianDirectorSell5,000$107.74$538,700.00View SEC Filing  
10/1/2014Stuart A ArbuckleEVPSell12,417$107.71$1,337,435.07View SEC Filing  
9/30/2014Amit SachdevSVPSell86,000$112.68$9,690,480.00View SEC Filing  
9/30/2014Ian F SmithCFOSell108,026$112.68$12,172,369.68View SEC Filing  
9/30/2014Jeffrey M LeidenCEOSell200,000$112.69$22,538,000.00View SEC Filing  
9/30/2014Kenneth L HortonEVPSell36,000$112.69$4,056,840.00View SEC Filing  
9/29/2014David AltshulerDirectorSell2,500$114.75$286,875.00View SEC Filing  
9/24/2014Joshua S BogerDirectorSell5,200$109.21$567,892.00View SEC Filing  
9/19/2014David AltshulerDirectorSell5,000$102.25$511,250.00View SEC Filing  
9/19/2014Paul M SilvaSVPSell25,408$99.85$2,536,988.80View SEC Filing  
9/19/2014Stuart A ArbuckleEVPSell55,521$100.00$5,552,100.00View SEC Filing  
9/17/2014Joshua S BogerDirectorSell5,200$93.62$486,824.00View SEC Filing  
9/10/2014Joshua S BogerDirectorSell5,200$94.42$490,984.00View SEC Filing  
9/5/2014David AltshulerDirectorSell2,500$94.75$236,875.00View SEC Filing  
9/3/2014Joshua S BogerDirectorSell5,200$92.79$482,508.00View SEC Filing  
8/27/2014Joshua S BogerDirectorSell5,200$93.31$485,212.00View SEC Filing  
8/20/2014Joshua S BogerDirectorSell5,200$91.51$475,852.00View SEC Filing  
8/13/2014Joshua S BogerDirectorSell5,200$88.00$457,600.00View SEC Filing  
8/6/2014Joshua S BogerDirectorSell5,200$86.54$450,008.00View SEC Filing  
7/31/2014David AltshulerDirectorSell5,000$89.59$447,950.00View SEC Filing  
7/31/2014Paul M SilvaSVPSell2,027$88.97$180,342.19View SEC Filing  
7/30/2014Joshua S BogerDirectorSell5,200$92.17$479,284.00View SEC Filing  
7/15/2014Wayne Joseph RileyDirectorSell4,800$96.65$463,920.00View SEC Filing  
7/1/2014Elaine UllianDirectorSell5,000$95.21$476,050.00View SEC Filing  
7/1/2014Kenneth L HortonEVPSell30,134$95.22$2,869,359.48View SEC Filing  
6/24/2014Megan E PaceSVPSell12,734$98.03$1,248,314.02View SEC Filing  
6/24/2014Wayne Joseph RileyDirectorSell15,000$98.03$1,470,450.00View SEC Filing  
6/16/2014Peter MuellerEVPSell7,500$68.31$512,325.00View SEC Filing  
6/9/2014Elaine UllianDirectorSell2,500$75.00$187,500.00View SEC Filing  
5/14/2014Peter MuellerEVPSell7,500$67.45$505,875.00View SEC Filing  
5/2/2014Megan PaceSVPSell1,000$67.62$67,620.00View SEC Filing  
4/15/2014Peter MuellerEVPSell7,500$61.63$462,225.00View SEC Filing  
4/9/2014Elaine UllianDirectorSell2,500$70.00$175,000.00View SEC Filing  
3/21/2014Bruce SachsDirectorSell8,700$74.59$648,933.00View SEC Filing  
3/17/2014Peter MuellerEVPSell7,500$78.29$587,175.00View SEC Filing  
2/7/2014Jeffrey LeidenCEOSell35,944$80.00$2,875,520.00View SEC Filing  
1/22/2014Bruce SachsDirectorSell8,300$84.47$701,101.00View SEC Filing  
1/21/2014Megan PaceSVPSell1,250$85.00$106,250.00View SEC Filing  
1/16/2014Jeffrey LeidenCEOSell45,000$80.00$3,600,000.00View SEC Filing  
1/15/2014Peter MuellerEVPSell7,500$78.67$590,025.00View SEC Filing  
12/23/2013Bruce SachsDirectorSell8,300$73.02$606,066.00View SEC Filing  
12/16/2013Peter MuellerEVPSell7,500$64.69$485,175.00View SEC Filing  
12/12/2013Jeffrey LeidenCEOSell9,834$65.48$643,930.32View SEC Filing  
12/12/2013Kenneth HortonEVPSell4,532$65.46$296,664.72View SEC Filing  
12/12/2013Megan PaceSVPSell5,083$65.48$332,834.84View SEC Filing  
12/4/2013Joshua BogerDirectorSell1,400$67.48$94,472.00View SEC Filing  
11/25/2013Joshua BogerDirectorSell1,400$66.89$93,646.00View SEC Filing  
11/20/2013Bruce SachsDirectorSell8,300$65.28$541,824.00View SEC Filing  
11/19/2013Joshua BogerDirectorSell1,400$62.31$87,234.00View SEC Filing  
11/5/2013Joshua BogerDirectorSell1,400$65.64$91,896.00View SEC Filing  
10/29/2013Joshua S BogerDirectorSell1,400$75.42$105,588.00View SEC Filing  
10/29/2013Thomas ConnollySVPSell1,688$75.04$126,667.52View SEC Filing  
10/24/2013Bruce I SachsDirectorSell8,300$77.06$639,598.00View SEC Filing  
10/23/2013Joshua S BogerDirectorSell1,400$76.77$107,478.00View SEC Filing  
10/16/2013Joshua S BogerDirectorSell1,400$75.41$105,574.00View SEC Filing  
10/15/2013Peter MuellerEVPSell7,500$73.25$549,375.00View SEC Filing  
10/14/2013Paul SilvaSVPSell1,593$71.87$114,488.91View SEC Filing  
10/9/2013Joshua BogerDirectorSell1,400$72.35$101,290.00View SEC Filing  
9/25/2013Joshua BogerDirectorSell1,400$74.72$104,608.00View SEC Filing  
9/18/2013Joshua BogerDirectorSell1,400$77.43$108,402.00View SEC Filing  
9/16/2013Peter MuellerEVPSell7,500$77.22$579,150.00View SEC Filing  
9/11/2013Joshua BogerDirectorSell1,400$79.61$111,454.00View SEC Filing  
9/4/2013Joshua BogerDirectorSell1,400$75.45$105,630.00View SEC Filing  
8/29/2013Bruce SachsDirectorSell8,300$77.19$640,677.00View SEC Filing  
8/28/2013Joshua BogerDirectorSell1,400$76.24$106,736.00View SEC Filing  
8/21/2013Joshua BogerDirectorSell1,400$76.96$107,744.00View SEC Filing  
8/15/2013Peter MuellerEVPSell7,500$77.41$580,575.00View SEC Filing  
8/14/2013Joshua BogerDirectorSell1,400$77.18$108,052.00View SEC Filing  
8/7/2013Joshua BogerDirectorSell1,400$77.84$108,976.00View SEC Filing  
8/5/2013Paul SilvaSVPSell3,001$78.90$236,778.90View SEC Filing  
7/31/2013Joshua S BogerDirectorSell1,400$80.89$113,246.00View SEC Filing  
7/29/2013Wayne Joseph RileyDirectorSell9,800$80.09$784,882.00View SEC Filing  
7/25/2013Paul M SilvaSVPSell1,125$86.49$97,301.25View SEC Filing  
7/24/2013Bruce I SachsDirectorSell8,300$85.50$709,650.00View SEC Filing  
7/19/2013Amit SachdevSVPSell22,250$88.69$1,973,352.50View SEC Filing  
7/18/2013Joshua S BogerDirectorSell1,400$86.12$120,568.00View SEC Filing  
7/16/2013Paul M SilvaSVPSell2,063$86.25$177,933.75View SEC Filing  
7/15/2013Christiana StamoulisSVPSell1,125$86.35$97,143.75View SEC Filing  
7/15/2013Peter MuellerEVPSell7,500$86.34$647,550.00View SEC Filing  
7/12/2013Megan E PaceSVPSell10,678$85.00$907,630.00View SEC Filing  
7/11/2013Joshua S BogerDirectorSell1,400$83.83$117,362.00View SEC Filing  
7/8/2013Kenneth L HortonEVPSell1,813$80.72$146,345.36View SEC Filing  
7/8/2013Megan E PaceSVPSell28,703$80.89$2,321,785.67View SEC Filing  
7/5/2013Christiana StamoulisSVPSell4,687$81.21$380,631.27View SEC Filing  
7/3/2013Joshua S BogerDirectorSell1,400$80.20$112,280.00View SEC Filing  
7/2/2013Peter MuellerEVPSell122,300$79.80$9,759,540.00View SEC Filing  
6/26/2013Joshua S BogerDirectorSell1,400$78.59$110,026.00View SEC Filing  
6/21/2013Bruce I SachsDirectorSell8,300$75.93$630,219.00View SEC Filing  
6/19/2013Joshua S BogerDirectorSell1,400$79.11$110,754.00View SEC Filing  
6/12/2013Joshua S BogerDirectorSell1,400$81.19$113,666.00View SEC Filing  
6/5/2013Joshua S BogerDirectorSell1,400$77.15$108,010.00View SEC Filing  
5/30/2013Joshua S BogerDirectorSell1,400$82.47$115,458.00View SEC Filing  
5/22/2013Joshua S BogerDirectorSell1,400$79.72$111,608.00View SEC Filing  
5/15/2013Joshua S BogerDirectorSell1,400$79.36$111,104.00View SEC Filing  
5/14/2013Bruce I SachsDirectorSell60,000$81.15$4,869,000.00View SEC Filing  
12/26/2012Joshua S BogerDirectorSell4,000$41.86$167,440.00View SEC Filing  
11/7/2012Margaret G McglynnDirectorBuy1,000$45.50$45,500.00View SEC Filing  
10/8/2012Ian F SmithCFOSell44,787$60.00$2,687,220.00View SEC Filing  
10/3/2012Joshua S BogerDirectorSell4,000$57.74$230,960.00View SEC Filing  
9/5/2012Joshua S BogerDirectorSell4,000$54.70$218,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Latest Headlines for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Source:
DateHeadline
zacks.com logoWhat's in Store for Vertex (VRTX) this Earnings Season?
www.zacks.com - April 24 at 6:56 PM
finance.yahoo.com logoWhat's in Store for Vertex (VRTX) this Earnings Season?
finance.yahoo.com - April 24 at 6:56 PM
americanbankingnews.com logoBarclays PLC Reaffirms "Equal Weight" Rating for Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - April 23 at 3:54 PM
americanbankingnews.com logoVertex Pharmaceuticals (VRTX) Given News Impact Rating of 0.04
www.americanbankingnews.com - April 22 at 11:59 AM
finance.yahoo.com logoTrump invites ​Vertex CEO to White House for biotech summit
finance.yahoo.com - April 21 at 8:47 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Cut to "Strong Sell" at Vetr Inc.
www.americanbankingnews.com - April 21 at 12:51 AM
americanbankingnews.com logoVertex Pharmaceuticals (VRTX) Given Daily News Sentiment Rating of 0.32
www.americanbankingnews.com - April 19 at 9:16 AM
finance.yahoo.com logo​Vertex at odds with religious investors over lobbying disclosures
finance.yahoo.com - April 18 at 7:42 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Short Interest Down 9.0% in March
www.americanbankingnews.com - April 18 at 9:36 AM
americanbankingnews.com logoZacks Investment Research Upgrades Vertex Pharmaceuticals Incorporated (VRTX) to Buy
www.americanbankingnews.com - April 18 at 7:45 AM
finance.yahoo.com logo​Vertex CEO's compensation, stock value fell in 2016
finance.yahoo.com - April 17 at 7:22 PM
americanbankingnews.com logoVertex Pharmaceuticals' (VRTX) "Buy" Rating Reaffirmed at JPMorgan Chase & Co.
www.americanbankingnews.com - April 16 at 12:17 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Stock Rating Upgraded by Vetr Inc.
www.americanbankingnews.com - April 16 at 8:18 AM
americanbankingnews.com logoVertex Pharmaceuticals (VRTX) Given Daily News Impact Rating of 0.13
www.americanbankingnews.com - April 14 at 2:06 PM
americanbankingnews.com logoEquities Analysts Issue Forecasts for Vertex Pharmaceuticals Incorporated's Q1 2017 Earnings (VRTX)
www.americanbankingnews.com - April 14 at 8:08 AM
finance.yahoo.com logoVertex to Announce First Quarter 2017 Financial Results on April 27
finance.yahoo.com - April 13 at 11:09 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) to Post Q3 2017 Earnings of $0.15 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 13 at 9:43 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 12 at 2:01 PM
americanbankingnews.com logo$460.26 Million in Sales Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter
www.americanbankingnews.com - April 12 at 12:39 PM
finance.yahoo.com logoProtalix Cystic Fibrosis Drug Study Results Worsen Over Time
finance.yahoo.com - April 12 at 10:45 AM
seekingalpha.com logoIt's Time To Take Profits On Vertex - Seeking Alpha
seekingalpha.com - April 10 at 8:05 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 10 at 2:44 PM
americanbankingnews.com logo$0.04 Earnings Per Share Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter
www.americanbankingnews.com - April 10 at 8:11 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Upgraded by Vetr Inc. to Sell
www.americanbankingnews.com - April 9 at 10:01 AM
americanbankingnews.com logoInsider Selling: Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells 8,021 Shares of Stock
www.americanbankingnews.com - April 7 at 7:59 PM
americanbankingnews.com logoQ1 2017 EPS Estimates for Vertex Pharmaceuticals Incorporated (VRTX) Increased by Analyst
www.americanbankingnews.com - April 7 at 7:38 PM
finance.yahoo.com logoVertex Pharmaceuticals (VRTX) Shares March Higher, Can It Continue?
finance.yahoo.com - April 7 at 1:26 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Rating Increased to Buy at Maxim Group
www.americanbankingnews.com - April 6 at 9:52 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Upgraded at Vetr Inc.
www.americanbankingnews.com - April 6 at 9:37 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) CMO Jeffrey Chodakewitz Sells 2,291 Shares
www.americanbankingnews.com - April 5 at 8:31 PM
fool.com logoIs Vertex Pharmaceuticals the Best Biotech Stock?
www.fool.com - April 5 at 4:00 PM
fool.com logoWhy Vertex Pharmaceuticals Rocketed 21.1% Higher in March
www.fool.com - April 4 at 6:45 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 2:04 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Stock Rating Reaffirmed by Credit Suisse Group AG
www.americanbankingnews.com - April 4 at 12:46 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Downgraded to "Strong Sell" at Vetr Inc.
www.americanbankingnews.com - April 4 at 8:39 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 4 at 8:38 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Receives "Neutral" Rating from HC Wainwright
www.americanbankingnews.com - April 2 at 7:55 PM
americanbankingnews.com logoPaul M. Silva Sells 1,688 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock
www.americanbankingnews.com - March 31 at 7:57 PM
americanbankingnews.com logoJeffrey Chodakewitz Sells 13,750 Shares of Vertex Pharmaceuticals Incorporated (VRTX) Stock
www.americanbankingnews.com - March 31 at 7:37 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) EVP Sells $8,664,215.00 in Stock
www.americanbankingnews.com - March 31 at 7:35 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Receives Outperform Rating from JMP Securities
www.americanbankingnews.com - March 31 at 12:38 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Raised to "Buy" at Maxim Group
www.americanbankingnews.com - March 31 at 11:31 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - March 30 at 8:55 PM
nasdaq.com logoVRTX Crosses Above Average Analyst Target
www.nasdaq.com - March 30 at 8:20 PM
us.rd.yahoo.com logoVertex: 'Calling Results Strong Does Not Make Them So'
us.rd.yahoo.com - March 30 at 8:20 PM
finance.yahoo.com logoVetr Turns Bearish On Vertex After Drug Trial Success
finance.yahoo.com - March 30 at 8:20 PM
feeds.benzinga.com logoCorbus Pharma's Positive Phase 2 Study: Safety First
feeds.benzinga.com - March 30 at 3:53 PM
streetinsider.com logoVertex Pharma (VRTX) Announce Positive Results for Two Ph3 Studies of Tezacaftor/Ivacaftor Combination Treatments - StreetInsider.com
www.streetinsider.com - March 30 at 8:17 AM
blogs.barrons.com logoThe Hot Stock: Vertex Pharmaceuticals Soars 20%
blogs.barrons.com - March 30 at 8:17 AM
finance.yahoo.com logoCorbus drug shows promise as add-on therapy for cystic fibrosis
finance.yahoo.com - March 30 at 8:17 AM

Social

Frequently Asked Questions for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

What is Vertex Pharmaceuticals Incorporated's stock symbol?

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

How were Vertex Pharmaceuticals Incorporated's earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings results on Wednesday, January, 25th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.06. The business earned $458.71 million during the quarter, compared to analyst estimates of $453.40 million. Vertex Pharmaceuticals Incorporated had a negative return on equity of 2.15% and a negative net margin of 6.76%. During the same period in the prior year, the business earned $0.17 earnings per share.

When will Vertex Pharmaceuticals Incorporated make its next earnings announcement?

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.

Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?

23 analysts have issued 12-month price targets for Vertex Pharmaceuticals Incorporated's shares. Their predictions range from $75.00 to $143.00. On average, they expect Vertex Pharmaceuticals Incorporated's share price to reach $108.10 in the next year.

What are analysts saying about Vertex Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

  • 1. According to Zacks Investment Research, "Vertex has two cystic fibrosis (CF) CF drugs – Kalydeco & Orkambi – in its portfolio with blockbuster potential. However, Vertex has faced many challenges with respect to commercialization of Orkambi in ex-U.S. markets. We believe the 2017 Orkambi revenue guidance is below expectations and dependent on reimbursement discussions in Europe. However, Vertex’s CF pipeline is quite strong.  Investor focus will now be on the triple combination CF regimens which are crucial for long-term growth at Vertex. Although the stock declined in 2016, it has done well this year.  Recently, positive data from two late-stage trials evaluating a combination of tezacaftor and Kalydeco pushed up the shares. Estimates have also gone up lately ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters. " (4/12/2017)
  • 2. Maxim Group analysts commented, "Vertex announced positive data from two pivotal studies of tezacaftor/ ivacaftor (tez/iva) in F508del homozygotes (EVOLVE) and in the first of two studies in heterozygotes (EXPAND, F508del/residual CFTR)." (3/31/2017)
  • 3. BMO Capital Markets analysts commented, "We believe Vertex's acquisition of Concert's CTP-656, a deuterated ivacaftor (Kalydeco), removes a key potential competitor in the cystic fibrosis space. In addition, CTP-656 could replace Kalydeco in the triple combo, allowing a once-daily (QD) regimen, which would offset an important advaVertex Pharma (NASDAQ: VRTX)ntage of Galapagos's QD triple combo in development. We also believe CTP-656's later patent expiration date (2032 vs. 2027 for Kalydeco) will be an important lifecycle management component of Vertex's cystic fibrosis franchise." (3/7/2017)
  • 4. Robert W. Baird analysts commented, "Vertex announced plans to acquire Concert Pharmaceuticals' CTP-656, or deuterated ivacaftor. We think this acquisition highlights Vertex's commitment to defending its position as the leading CF company as it both eliminates a potential competitor and allows access to a once-daily modified version of ivacaftor with a longer patent life than ivacaftor itself. Overall, we think this is a smart deal for the company at a reasonable price, and reiterate our Outperform rating." (3/6/2017)
  • 5. Cowen and Company analysts commented, "Last week we hosted meetings with Vertex management in Chicago." (2/11/2017)

Are investors shorting Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals Incorporated saw a decrease in short interest in March. As of March 31st, there was short interest totalling 4,560,968 shares, a decrease of 9.0% from the March 15th total of 5,011,657 shares. Based on an average daily trading volume, of 2,749,188 shares, the days-to-cover ratio is presently 1.7 days.

Who owns Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Manning & Napier Advisors LLC (0.71%), Factory Mutual Insurance Co. (0.11%), Chevy Chase Trust Holdings Inc. (0.10%), Candriam Luxembourg S.C.A. (0.09%), National Pension Service (0.08%) and Gateway Investment Advisers LLC (0.07%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Paul M Silva, Stuart A Arbuckle, Terrence C Kearney and Yuchun Lee.

Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Nationwide Fund Advisors, Factory Mutual Insurance Co., Cullinan Associates Inc., Candriam Luxembourg S.C.A., Taylor Wealth Management Partners, Hartford Investment Management Co. and Creative Planning. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, Ian F Smith, Jeffrey Chodakewitz, Joshua S Boger, Paul M Silva and Stuart A Arbuckle.

Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Gateway Investment Advisers LLC, Retirement Systems of Alabama, Bank of Montreal Can, Chevy Chase Trust Holdings Inc., Parametrica Management Ltd, National Pension Service and Nisa Investment Advisors LLC.

How do I buy Vertex Pharmaceuticals Incorporated stock?

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vertex Pharmaceuticals Incorporated stock cost?

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $117.66.

Vertex Pharmaceuticals Incorporated (VRTX) Chart for Monday, April, 24, 2017

This page was last updated on 4/24/2017 by MarketBeat.com Staff